91 related articles for article (PubMed ID: 16213748)
21. TNF-alpha induces changes in LDH isotype profile following triggering of apoptosis in PBL of non-Hodgkin's lymphomas.
Jurisic V; Bumbasirevic V; Konjevic G; Djuricic B; Spuzic I
Ann Hematol; 2004 Feb; 83(2):84-91. PubMed ID: 14586559
[TBL] [Abstract][Full Text] [Related]
22. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
23. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
24. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
Alas S; Emmanouilides C; Bonavida B
Clin Cancer Res; 2001 Mar; 7(3):709-23. PubMed ID: 11297268
[TBL] [Abstract][Full Text] [Related]
26. Melatonin inhibits cell proliferation and induces caspase activation and apoptosis in human malignant lymphoid cell lines.
Sánchez-Hidalgo M; Lee M; de la Lastra CA; Guerrero JM; Packham G
J Pineal Res; 2012 Nov; 53(4):366-73. PubMed ID: 22582944
[TBL] [Abstract][Full Text] [Related]
27. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.
Vockerodt M; Wei W; Nagy E; Prouzova Z; Schrader A; Kube D; Rowe M; Woodman CB; Murray PG
J Pathol; 2013 Aug; 230(4):399-409. PubMed ID: 23592216
[TBL] [Abstract][Full Text] [Related]
28. Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma.
Traullé C; Coiffier BB
Future Oncol; 2005 Jun; 1(3):297-306. PubMed ID: 16556002
[TBL] [Abstract][Full Text] [Related]
29. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
Alas S; Ng CP; Bonavida B
Clin Cancer Res; 2002 Mar; 8(3):836-45. PubMed ID: 11895917
[TBL] [Abstract][Full Text] [Related]
30. Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping.
Reinhold WC; Kouros-Mehr H; Kohn KW; Maunakea AK; Lababidi S; Roschke A; Stover K; Alexander J; Pantazis P; Miller L; Liu E; Kirsch IR; Urasaki Y; Pommier Y; Weinstein JN
Cancer Res; 2003 Mar; 63(5):1000-11. PubMed ID: 12615715
[TBL] [Abstract][Full Text] [Related]
31. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
32. GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment.
Meyer zum Büschenfelde C; Feuerstacke Y; Götze KS; Scholze K; Peschel C
Cancer Res; 2008 Jul; 68(13):5414-22. PubMed ID: 18593944
[TBL] [Abstract][Full Text] [Related]
33. Α-tubulin nuclear overexpression is an indicator of poor prognosis in patients with non-Hodgkin's lymphoma.
Hayashi S; Mikami T; Murai Y; Takano Y; Imura J
Int J Mol Med; 2014 Aug; 34(2):483-90. PubMed ID: 24898903
[TBL] [Abstract][Full Text] [Related]
34. Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.
Maxwell SA; Mousavi-Fard S
Exp Biol Med (Maywood); 2013 Sep; 238(9):971-90. PubMed ID: 23986223
[TBL] [Abstract][Full Text] [Related]
35. mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma.
Staber PB; Noehammer C; Dürkop H; Schauer S; Kenner L; Linkesch W; Hoefler G
Leuk Res; 2006 Mar; 30(3):343-8. PubMed ID: 16198418
[TBL] [Abstract][Full Text] [Related]
36. Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs.
Fiebig HH; Schüler J; Bausch N; Hofmann M; Metz T; Korrat A
Cancer Genomics Proteomics; 2007; 4(3):197-209. PubMed ID: 17878523
[TBL] [Abstract][Full Text] [Related]
37. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis.
Stamatopoulos B; Meuleman N; De Bruyn C; Mineur P; Martiat P; Bron D; Lagneaux L
Leukemia; 2009 Dec; 23(12):2281-9. PubMed ID: 19710697
[TBL] [Abstract][Full Text] [Related]
38. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.
Hernandez-Ilizaliturri FJ; Reddy N; Holkova B; Ottman E; Czuczman MS
Clin Cancer Res; 2005 Aug; 11(16):5984-92. PubMed ID: 16115943
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas.
Doglioni C; Pelosio P; Mombello A; Scarpa A; Chilosi M
Hematol Pathol; 1991; 5(2):67-73. PubMed ID: 1680118
[TBL] [Abstract][Full Text] [Related]
40. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
